Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.
Mil Med Res
; 7(1): 19, 2020 04 20.
Article
in English
| MEDLINE | ID: covidwho-72008
ABSTRACT
Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Blood Coagulation Disorders
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Humans
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Mil Med Res
Year:
2020
Document Type:
Article
Affiliation country:
S40779-020-00247-7
Similar
MEDLINE
...
LILACS
LIS